Fair value · BeOne Medicines Ltd. (ONC) · updated 2026-10-02 · from 20-F FY2025
BeOne Medicines trades at $352.36. We are not reading assumptions out of that price: this is a depositary receipt and we cannot show whether its per-share figures are stated per ADS or per ordinary share, so these methods are withheld rather than shown at a scale we cannot verify.
Everything below is unaffected: the filed statements, the filing they came from, and ONC’s growth history are all as reported.
The filing behind these numbers
BeOne Medicines Ltd.- Revenue
- $5.3B
- Diluted EPS
- $0.19
- Free cash flow
- $941.7M
- operating cash flow − capital expenditure
- Diluted shares
- 1.47B
- weighted average
20-F FY2025 · fiscal year ended 2025-12-31 · filed 2026-02-26 · accession 0001628280-26-011946
Trailing-twelve-month EPS also uses the quarterly 6-Ks through Q2 FY2026 (filed 2026-08-05).
Open this filing on sec.govNeed ONC data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.